Table 2 Uncorrected and PCR-corrected treatment outcomes at days 28 and 42 for artemether-lumefantrine (AL) and artesunate-amodiaquine (ASAQ), Mali 2015–2016

Uncorrected treatment outcomes—day 28

 Number reaching an endpoint

217

217

 Early treatment failure

14

6.5%

3.2%

9.7%

3

1.4%

0.0%

2.9%

0.006

 Late clinical failure

10

4.6%

5

2.3%

 Late parasitological failure

12

5.5%

7

3.2%

 Adequate clinical and parasitological response at day 28

181

83.4%

78.5%

88.4%

202

93.1%

89.7%

96.5%

0.002

Uncorrected treatment outcomes—day 42

 Number reaching an endpoint

212

214

 Early treatment failure

14

6.6%

3.3%

9.9%

3

1.4%

0.0%

3.0%

0.006

 Late clinical failure

15

7.1%

9

4.2%

 Late parasitological failure

29

13.7%

22

10.3%

Adequate clinical and parasitological response at day 42

154

72.6%

66.6%

78.6%

180

84.1%

78.3%

89.9%

0.004

PCR corrected treatment outcomes—day 28

 Number reaching an endpoint

217

217

 Early treatment failure

14

6.5%

3.2%

9.7%

3

1.4%

0.0%

2.9%

0.006

 Recrudescent cases

4

1.8%

3

1.4%

 Total new infections

18

8.3%

9

 Day 7–14

1

2

 Day 15–21

10

1

 Day 22–28

7

6

 Adequate clinical and parasitological response at day 28

181

91.0%

86.0%

95.9%

202

97.1%

93.6%

100.0%

0.008

PCR corrected treatment outcomes—day 42

 Number reaching an endpoint

212

214

 Early treatment failure

14

6.6%

3.3%

9.9%

3

1.4%

0.0%

3.0%

0.006

 Recrudescent cases

5

2.4%

4

1.9%

 Total new infections

39

18.4%

27

12.6%

 Day 7–14

1

2

 Day 15–21

10

1

 Day 22–28

7

6

 Day 29–35

16

12

 Day 36–42

5

6

 Adequate clinical and parasitological response at day 42

154

89.0%

83.0%

95.0%

180

96.3%

91.0%

100.0%

0.008